Zydus Cadila has received the final approval from the USFDA to market Potassium Chloride Extended-Release Capsules USP (US RLD - Micro-K® Extended-Release Capsules), 8 mEq (600 mg) and 10 mEq (750 mg). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium helps your cells, kidneys, heart, muscles and nerves work properly. Some conditions that can lower the body's potassium level include severe prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism, or treatment with 'water pills' / diuretics.
The group now has 254 approvals and has so far filed over 350 ANDAs since the commencement ofthe filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.336 as compared to the previous close of Rs. 332.7. The total number of shares traded during the day was 144902 in over 1809 trades.
The stock hit an intraday high of Rs. 342.95 and intraday low of 332.6. The net turnover during the day was Rs. 49148776.